XETRA · MRK.DE
Merck KGaA
€150.55+€0.25 (+0.17%)
Merck KGaA’s quoted price sits in the upper half of its reported 52-week range, 1.02% below the high.
Loading market information…
NASDAQ · HUGE · USD
Stock price, earnings
Quote as of Aug 14, 2024, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
FSD Pharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.92% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow FSD Pharma Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
FSD Pharma Inc. is a biopharmaceutical research and development company, operating through its various subsidiaries. The firm's leading drug candidate, FSD-201, is currently undergoing Phase II clinical trials for the treatment of COVID-19 disease. Additionally, FSD Pharma is actively developing Lucid-PSYCH, a psychoactive molecule identified for its potential in addressing neuropsychiatric conditions such as depressive disorder. They are also advancing Lucid-MS, a proprietary new chemical entity which, in preclinical models, has demonstrated the capacity to prevent and reverse myelin degradation—the fundamental mechanism behind multiple sclerosis. Established in 1998, FSD Pharma Inc. is headquartered in Toronto, Canada.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:31 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $0.00 |
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
€150.55+€0.25 (+0.17%)
Merck KGaA’s quoted price sits in the upper half of its reported 52-week range, 1.02% below the high.
CA$1.99+CA$0.05 (+2.58%)
Cannara Biotech Inc.’s quoted price sits in the upper half of its reported 52-week range, 16.03% below the high.
CA$0.20CA$0.00 (0.0%)
Leef Brands Inc.’s quoted price sits in the lower half of its reported 52-week range, 38.46% below the high.
$0.90-$0.03 (-3.38%)
Biofrontera Inc.’s quoted price sits in the lower half of its reported 52-week range, 45.78% below the high.
$0.01$0.00 (0.0%)
Cann American Corp.’s quoted price sits in the upper half of its reported 52-week range, 43.88% below the high.
CA$0.03CA$0.00 (0.0%)
City View Green Holdings Inc.’s quoted price sits in the lower half of its reported 52-week range, 76.92% below the high.
$0.00-$0.00 (-14.29%)
SOHM, Inc.’s quoted price sits in the lower half of its reported 52-week range, 60.0% below the high.
$0.51-$0.16 (-23.29%)
Lucy Scientific Discovery Inc.’s quoted price sits in the lower half of its reported 52-week range, 95.99% below the high.
